Synchron Pauses Stentrode Brain Implant Trial

The New York company is halting enrollment in its INTENT trial after the device failed to perform as expected in early participants.

Updated on Nov. 20, 2026 in Stroke

Bold flat-color vector editorial illustration of a coiled pale lead with gold contact pads, one segment kinked and marked in coral, on a slate field.
Synchron paused enrollment in its INTENT brain-implant trial after a lead issue was identified in the second-generation Stentrode device, which has already been implanted in some participants. AI Illustration. Upload story photo >

Synchron has paused enrollment in its INTENT clinical trial of the second-generation Stentrode brain-computer interface. WIRED reported the device failure on Nov. 12, and the company has identified a lead issue with the device.

Why it matters

The pause delays progress on a brain-computer interface intended for patients with paralysis, and it signals that hardware problems remain a hurdle for implanted neural devices. Participants who already received the Stentrode will continue to be monitored as the company works on fixes.

The evidence is a company statement on trial status following early device performance problems, with no enrollment or outcome figures disclosed. The timeline for resuming the INTENT trial and the specifics of the lead defect remain unresolved.

The players

Synchron

Synchron is a New York-based medical technology company developing the Stentrode, a minimally invasive brain-computer interface implanted through blood vessels.

The details

Synchron paused enrollment in the INTENT trial after identifying a lead issue with its second-generation Stentrode device, which has already been implanted in some participants. The company plans to resume the trial once hardware upgrades are completed.

Timeline

  1. Nov. 12, 2026: WIRED reported the device failure and the trial pause.

  2. Nov. 19, 2026: Medtech Insight published its coverage of the pause.

Roadmap

The pause places the Stentrode's INTENT trial, a key effort to bring endovascular brain-computer interfaces toward regulatory review, behind schedule. The upgraded second-generation system must now prove reliable before the program can advance.

Patients with paralysis who hoped to enroll in the INTENT trial will have to wait until Synchron resumes enrollment after the hardware upgrades. Anyone considering a brain-computer interface should expect that early-stage implanted devices can still require redesigns.

The takeaway

Early device failures are a normal part of developing implanted brain-computer interfaces, and trials often pause to fix hardware before advancing. Readers tracking this technology should watch for Synchron's announcement of when the INTENT trial resumes.

Further reading

For related coverage of treatments and devices tied to brain health, explore the Stroke section.

Source note: This article includes information reported by Insights.